4月14日 - ** 制药商百时美施贵宝BMY.N股价在延时交易中下跌1.6%，至50.50美元
** 该公司称其试验性心脏病药物mavacamten在一项后期研究中没有达到主要目标 (link)
** 该药物正在接受测试，以治疗患有所谓非阻塞性肥厚型心肌病的成年患者(nHCM)，这是一种以心脏肌肉增厚为特征的遗传性疾病。
** 这种名为 "Camzyos "的药物并没有改善 nHCM 患者的症状，也没有让他们更容易锻炼身体。
** 该药在美国已被批准用于治疗阻塞性心脏病
** 截至上一交易日收盘，股价累计下跌 9.2
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.